CLYM — Climb Bio, Inc. stock price, charts and financials

QT92Climb Bio, Inc.

Climb Bio, Inc. (NASDAQ: CLYM) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
14.05
-0.01-0.07%
OverviewShort InterestFilings
CLYMQT92Climb Bio, Inc.·NASDAQ
14.05-0.07%
TA
Loading chart...
Signal & projected range
Insider open-market saleHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-Insider Own45.85%Shs Outstand57.26MPerf Week-1.40%
Market Cap804.55MForward P/E-EPS next Y-0.98Insider Trans-0.50%Shs Float49.20MPerf Month-18.97%
Enterprise Value622.55MPEG-EPS next Q-0.19Inst Own-Short Float14.84%Perf Quarter22.71%
Income-60.00MP/S0.00EPS this Y-Inst Trans-Short Ratio5.45Perf Half Y101.29%
Sales0.00P/B3.35EPS next Y-23.34%ROA-23.40%Short Interest7.30MPerf YTD251.25%
Book/sh4.19P/C4.40EPS next 5Y-ROE-31.79%52W High18.33 -23.35%Perf Year562.74%
Cash/sh3.20P/FCF-EPS past 3/5Y-ROIC-26.89%52W Low1.54 812.34%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility5.73% 7.57%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM45.75%Oper. Margin0.00%ATR (14)1.11Perf 10Y-
Dividend Ex-Date-Quick Ratio31.45Sales Y/Y TTM-Profit Margin0.00%RSI (14)45.17Recom2.00
Dividend Gr. 3/5Y-Current Ratio31.45EPS Q/Q-38.46%SMA20-6.89%Beta1.84Target Price26.55
Payout0.00%Debt/Eq0.00Sales Q/Q-SMA50-1.46%Rel Volume2.71Prev Close14.06
Employees28LT Debt/Eq0.00EarningsNov 11SMA20051.37%Avg Volume1.50MPrice14.05
IPO DateAug 10, 2021Option/ShortYes / YesEPS/Sales Surpr.14.00% -Net Debt/EBITDA0.72Volume4,049,708Change-0.07%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-08-26ReiteratedOppenheimerOutperform$25
Sep-08-26ReiteratedHC Wainwright & Co.Buy$24 → $30
Sep-03-26ReiteratedRobert W. Baird$21 → $25
Sep-03-26ReiteratedPiper Sandler$23 → $40
Sep-03-26ReiteratedBTIGBuy$20 → $32
Aug-24-26ReiteratedHC Wainwright & Co.Buy$20 → $24
Aug-07-26ReiteratedTruist SecuritiesBuy$17 → $25
Aug-03-26InitiatedRBC CapitalOutperform$23
Jun-11-26ReiteratedBTIGBuy$20
Jun-08-26InitiatedGuggenheimBuy$35
Latest News· Times ET
Sep-08-26
Sep-08-2608:55AM
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25Benzinga
Sep-03-26
Sep-03-2610:14AM
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32Benzinga
10:02AM
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drugmarketbeat.com
09:52AM
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedulebenzinga.com
03:00AM
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathyglobenewswire.com
Sep-02-26
Sep-02-2603:00AM
Climb Bio to Present at Upcoming Investor Conferencesglobenewswire.com
Aug-24-26
Aug-24-2602:04AM
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $24Benzinga
Aug-19-26
Aug-19-2604:46AM
Wedbush Reiterates Outperform on Climb Bio, Maintains $20 Price TargetBenzinga
Aug-07-26
Aug-07-2605:13AM
Truist Securities Maintains Buy on Climb Bio, Raises Price Target to $25Benzinga
Jul-27-26
Jul-27-2609:21PM
Climb Bio (NASDAQ:CLYM) Shares Up 10.9% Following Analyst Upgradedefenseworld.net
09:21PM
Climb Bio (NASDAQ:CLYM) Sets New 52-Week High Following Analyst Upgradedefenseworld.net
05:03AM
Wedbush Maintains Outperform on Climb Bio, Raises Price Target to $20Benzinga
Jul-23-26
Jul-23-2608:27AM
Climb Bio: Three Key Kidney Disease Readouts In Q4 Ought To Generate Volatilityseekingalpha.com
Jun-24-26
Jun-24-2602:50AM
HC Wainwright & Co. Reiterates Buy on Climb Bio, Maintains $20 Price TargetBenzinga
Jun-12-26
Jun-12-2612:25PM
Climb Bio Launches $100M At-The-Market Common Stock Offering Via JefferiesBenzinga
Company

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue
000————
Cost of Goods Sold Incl. D&A
000————
Gross Profit
000————
Selling, General and Administrative Excl. Other211625————
Research and Development471415————
Other Operating Expense0520————
Operating Income-68-82-40————
Interest Expense
000————
Unusual Expense
———————
Non-Operating Income (Expense)885————
Net Income Before Taxes-60-74-35————
Income Taxes
000————
Consolidated Net Income-60-74-35————
Net Income From Continuing Operations-60-74-35————
Net Income-60-74-35————
EPS (Recurring)-0.88-1.53-1.30————
EPS (Basic, Before Extraordinaries)-0.88-1.53-1.30————
EPS (Diluted)-0.88-1.53-1.30————
EBITDA-60-30-35————
Other After Tax Adjustments
———————
Stock Option Compensation Expense
———————
Price To Earnings Ratio
———————
Price To Sales Ratio
———————
Gross Margin
———————
Operating Margin
———————
Net Margin
———————
Shares Outstanding684827————
Market Capitalization27286—————
Operating Lease Expense
———————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$20.31$14.96$9.61$4.25$-1.10● Close Price0.00M0.34M0.68M1.03M1.37MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Thomas Stephen BasilDirectorSep 15 '26Sale13.67100,0001,366,820467,969Sep 17
Brennan AoifePresident and CEOJun 29 '26Sale13.1730,902406,97987,731Jun 30
Brennan AoifePresident and CEOJun 27 '26Option Exercise0.0068,7500118,633Jun 30
Thomas Stephen BasilDirectorFeb 26 '26Sale7.0116,313114,289154,657Feb 27
Thomas Stephen BasilDirectorFeb 25 '26Sale7.0033,687235,964170,970Feb 27
Thomas Stephen BasilDirectorFeb 13 '26Sale5.8110,00058,141204,657Feb 17
Thomas Stephen BasilDirectorFeb 12 '26Sale5.2390,000470,988214,657Feb 17
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Jan 05 '26Buy3.507,11124,8893,403,429Jan 07
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Dec 12 '25Buy2.86101,462290,1813,396,318Dec 15
RA CAPITAL MANAGEMENT, L.P.director, 10 percent owner:Dec 11 '25Buy2.18213,099464,5563,294,856Dec 15
Brennan AoifePresident and CEOJun 30 '25Sale1.2220,61825,15448,132Jul 01
Thomas Stephen BasilDirectorJun 27 '25Option Exercise0.0025,0940204,282Jul 01
Brennan AoifePresident and CEOJun 27 '25Option Exercise0.0068,750068,750Jul 01
Pimblett EmilySVP, Finance & CAOJun 20 '25Sale1.241,2421,54018,888Jun 20
Pimblett EmilySVP, Finance & CAOJun 18 '25Option Exercise0.005,000020,130Jun 20
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.